Bioinfra Co., Ltd. (199730)
Market Closed
11 Aug, 06:30
KRX SM KRX SM Primary ₩
1,794. 00
+77
+4.4846%
₩
22.67B Market Cap
- P/E Ratio
400% Div Yield
43,220 Volume
- Eps
₩ 1,717
Previous Close Want to track 199730 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
199730 closed today higher at ₩1,794, an increase of 4.4846% from yesterday's close, completing a monthly decrease of -22% or -₩506. Over the past 12 months, 199730 stock lost -62.0719%.
199730 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.
Bioinfra Co., Ltd. (199730) FAQ
What is the stock price today?
The current price is ₩1,794.00.
On which exchange is it traded?
Bioinfra Co., Ltd. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 199730.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 400%.
What is its market cap?
As of today, the market cap is 22.67B.
Has Bioinfra Co., Ltd. ever had a stock split?
No, there has never been a stock split.
Bioinfra Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | KRX SM Exchange | - ISIN |
| KR Country | - Employees | 29 Dec 2025 Last Dividend | - Last Split | - IPO Date |
Overview
Bioinfra Co., Ltd. is a distinguished contract research organization that focuses on conducting phase 1 clinical trials. Founded in 2007, the company has cemented its presence as a key player in the pharmaceutical research industry, with its headquarters located in Yongin-si, South Korea. Bioinfra Co., Ltd. specializes in offering comprehensive clinical trial services, especially for new and generic pharmaceutical products, showcasing a commitment to advancing pharmaceutical research and development by ensuring the safety and efficacy of drugs before they reach the market.
Products and Services
Bioinfra Co., Ltd. offers a range of specialized services designed to support the pharmaceutical industry in various stages of drug development. These include:
- Bioequivalence Test for Generic Drugs: This service focuses on comparing the bioavailability of a generic drug to that of the original brand name drug. Bioequivalence tests are crucial for the approval of generic drugs, ensuring they meet the necessary efficacy and safety standards.
- Phase 1 Test for Incrementally Modified Drugs: Bioinfra Co., Ltd. also conducts phase 1 clinical trials for incrementally modified drugs (IMDs). These trials are designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of new formulations or combinations of existing drugs, thereby supporting the development of drugs with improved efficacy, safety, or patient compliance.
- Phase 1 Sample Analysis for Other New Substances: The company offers comprehensive sample analysis services for a wide range of new substances undergoing phase 1 clinical trials. This includes the assessment of pharmacokinetic parameters, metabolite analysis, and safety biomarkers, providing critical data for the early-stage development of new pharmaceutical compounds.
Contact Information
Address: 120 Heungdeokjungang-ro
Phone: 82 3 1888 6270
Website: https://www.bioinfrakorea.co.kr
